LunarCrush LLM | creator/twitter::1035490068/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@gcfmd](/creator/twitter/gcfmd)
"Amgen announced the Phase X VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that evolocumab significantly reduced the risk of MACE in individuals without a prior history of heart attack or stroke 12000 high-risk patients median of XXX years @kewatson"  
[X Link](https://x.com/gcfmd/status/1973913387513135504) [@gcfmd](/creator/x/gcfmd) 2025-10-03T00:49Z 11.9K followers, 1853 engagements


"direct-to-consumer evolocumab (Repatha) to be available at a discounted cash price of $XXX a month Amgen to sell cholesterol drug at XX% discount to cash-paying US patients @kewatson @boback @pnatarajanmd @kardiologykazi"  
[X Link](https://x.com/gcfmd/status/1975535280250929534) [@gcfmd](/creator/x/gcfmd) 2025-10-07T12:14Z 11.9K followers, 2861 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@gcfmd "Amgen announced the Phase X VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that evolocumab significantly reduced the risk of MACE in individuals without a prior history of heart attack or stroke 12000 high-risk patients median of XXX years @kewatson"
X Link @gcfmd 2025-10-03T00:49Z 11.9K followers, 1853 engagements

"direct-to-consumer evolocumab (Repatha) to be available at a discounted cash price of $XXX a month Amgen to sell cholesterol drug at XX% discount to cash-paying US patients @kewatson @boback @pnatarajanmd @kardiologykazi"
X Link @gcfmd 2025-10-07T12:14Z 11.9K followers, 2861 engagements